Copyright
©The Author(s) 2021.
World J Clin Oncol. Mar 24, 2021; 12(3): 183-194
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.183
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.183
Type/pathologic stage of testicular tumor | RPLN ≥ 3.0 cm before chemotherapy | Type/number of cycles of chemotherapy | PE/DVT | Timing of PE/DVT in relation to chemotherapy | Anticoagulant | Hospitalization |
Seminoma IIB | Yes | BEP (2 cycles), EP (1 cycles) | DVT | Same day immediately prior to Cycle 1 | Fondaparinux sodium | Yes |
Seminoma IIA | No | EP (3 cycles) | DVT1 | During (Cycle 1) | Heparin → apixaban | Yes |
Seminoma IIIB | No | EP (4 cycles) | PE + DVT2 | 3 yr after initial chemotherapy, recurrent disease | Enoxaparin sodium | Yes |
Non-seminoma IIB | Yes | BEP (2 cycles) | DVT2 | During (Cycle 2) | Warfarin →enoxaparin sodium | Yes |
Non-seminoma IIB | No | BEP (3 cycles) | PE | During (Cycle 2) | Heparin → enoxaparin sodium → rivaroxaban → apixaban | Yes |
Non-seminoma IIC | Yes | EP (4 cycles) | PE + DVT | 1 wk before Cycle 1 | Heparin (lovenox) → warfarin | Yes |
Non-seminoma IIA | No | BEP (3 cycles) | DVT2 | During (Cycle 2) | Fondaparinux sodium | No |
Non-seminoma IIB | Yes | BEP (3 cycles) | PE1 | During (Cycle 3) | Fondaparinux sodium → warfarin | No |
Seminoma IIA | No | BEP (3 cycles) | DVT2 | During (Cycle 3) | None | No |
Seminoma III | No | BEP (3 cycles) | PE | During (Cycle 3) | Enoxaparin sodium | No |
Non-seminoma IIIC | Yes | BEP (4 cycles) | PE | During (Cycle 4) | Enoxaparin sodium | No |
Non-seminoma IIIC | Yes | BEP (4 cycles) | DVT | During (Cycle 3) | Enoxaparin sodium | No |
Non-seminoma IIA | No | BEP (3 cycles) | PE | During (Cycle 3) | Heparin → rivaroxaban | Yes |
Non-seminoma IIA | No | BEP (2 cycles) | PE | During (Cycle 2) | Enoxaparin sodium | No |
Seminoma IIC | Yes | BEP (3 cycles) | PE | 1 mo after chemotherapy ended | Heparin → enoxaparin sodium | Yes |
Seminoma IIA | No | BEP (3 cycles) | PE + DVT | During (Cycle 2) | Heparin → enoxaparin sodium | Yes |
Non-seminoma IIB | No | BEP (3 cycles) | DVT | 1 d prior to Cycle 1 | Heparin → fondaparinux sodium | Yes |
Non-seminoma IIIA | No | BEP (3 cycles) | PE | 2 wk after chemotherapy ended | Warfarin + enoxaparin sodium | No |
Seminoma IIC | Yes | EP (4 cycles) | DVT2 | During (Cycle 2) | Enoxaparin sodium → fondaparinux | Yes |
- Citation: Shields LBE, Daniels MW, Mar N, Rezazadeh Kalebasty A. Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy. World J Clin Oncol 2021; 12(3): 183-194
- URL: https://www.wjgnet.com/2218-4333/full/v12/i3/183.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i3.183